E
INZY

Ergoteles’s Inozyme Pharma INZY Stock Holding History

Ergoteles’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,649
Closed -$122K – 1740
2022
Q2 		$122K Buy
+25,649
New +$112K ﹤0.01% 1466
2022
Q1 		– Sell
-12,200
Closed -$83K – 1419
2021
Q4 		$83K Buy
+12,200
New +$105K ﹤0.01% 1165

Other funds holding INZY

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ergoteles's INZY Position: Q3 2022 in Review

Ergoteles sold out of Inozyme Pharma (INZY) in Q3 2022, closing a stake of 25,649 shares — an estimated $122K sold.

Ergoteles first reported a position in INZY in Q4 2021 and held it in 2 quarters. The position peaked at $122K in Q2 2022. 39 funds tracked by Wall St. Rank hold INZY as of Q3 2022.

  • Ergoteles reported no remaining Inozyme Pharma position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 25,649 Inozyme Pharma shares in Q3 2022, an estimated $122K.
  • Ergoteles first reported a position in Inozyme Pharma in Q4 2021 and held it in 2 quarters.
  • Ergoteles's Inozyme Pharma position peaked at $122K in Q2 2022.
  • 39 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.